2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.
2′-Hydroxyflavanone
Breast Cancer
Estrogen receptor
Mass spectrometry
TMT 10plex
Journal
Journal of proteomics
ISSN: 1876-7737
Titre abrégé: J Proteomics
Pays: Netherlands
ID NLM: 101475056
Informations de publication
Date de publication:
10 02 2019
10 02 2019
Historique:
received:
18
07
2018
revised:
03
09
2018
accepted:
10
09
2018
pubmed:
25
9
2018
medline:
27
2
2020
entrez:
25
9
2018
Statut:
ppublish
Résumé
In spite of rapid advances in understanding of signaling networks associated with the incidence and therapeutic-sensitivity, breast cancer (BC) still remains the most commonly diagnosed and prevalent cancer in women. Emergence of resistance to hormonal interventions in estrogen-receptor (ER) positive BC coupled to loss of ER expression and activation of ER-independent growth factor, heat-shock, MYC and WNT pathways along with distinct mechanisms of therapeutic-resistance in HER2 over-expressing and triple-negative subtypes of BC collectively necessitates deeper profiling of the mechanistic networks regulated by potential lead anticancer compounds intended for further development to target BC. A significant part of the search for novel lead anticancer compounds for BC has focused on phytochemicals including flavonoids found in citrus fruits, which have shown promising anticancer activity. Based on the initial studies which revealed the anticancer effect of 2HF in BC, we employed an advanced TMT 10plex labeled proteomic approach to characterize the changes in non-phosphorylated and phosphorylated proteomic profile of ER
Identifiants
pubmed: 30248461
pii: S1874-3919(18)30346-4
doi: 10.1016/j.jprot.2018.09.005
pmc: PMC8817450
mid: NIHMS1772521
pii:
doi:
Substances chimiques
2'-hydroxyflavanone
0
Antineoplastic Agents
0
Flavanones
0
Neoplasm Proteins
0
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
233-245Subventions
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.
Références
BMC Genomics. 2008 Jul 24;9:348
pubmed: 18652687
Mol Cell Biol. 2001 Jun;21(12):3995-4004
pubmed: 11359907
Biochem Biophys Res Commun. 2007 Mar 2;354(1):190-6
pubmed: 17222798
J Transl Med. 2014 Dec 14;12:354
pubmed: 25496516
J Neuroendocrinol. 2009 Mar;21(4):229-37
pubmed: 19207820
Carcinogenesis. 2006 Aug;27(8):1567-78
pubmed: 16474171
PLoS One. 2009 Aug 19;4(8):e6693
pubmed: 19690609
Cell Mol Life Sci. 2015 Apr;72(7):1249-60
pubmed: 25433395
Cell Rep. 2014 Jul 24;8(2):410-9
pubmed: 25043189
PLoS One. 2014 Jun 30;9(6):e101004
pubmed: 24979213
Int J Cancer. 2008 Jul 1;123(1):236-40
pubmed: 18398844
Breast Cancer Res. 2014 Sep 11;16(5):430
pubmed: 25212826
Oncotarget. 2017 Jan 24;8(4):6246-6257
pubmed: 28009981
Nat Commun. 2015 Mar 12;6:6439
pubmed: 25762514
Cancer Surv. 1996;27:271-92
pubmed: 8909805
Oncotarget. 2017 Jul 25;8(30):49370-49379
pubmed: 28472761
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9119-24
pubmed: 21571647
Clin Cancer Res. 2016 Oct 1;22(19):4923-4933
pubmed: 27143691
BMC Cancer. 2015 Nov 02;15:832
pubmed: 26526356
J Proteome Res. 2017 Mar 3;16(3):1121-1132
pubmed: 28102081
Nat Commun. 2016 Feb 04;7:10633
pubmed: 26843124
PLoS One. 2013 Dec 31;8(12):e85737
pubmed: 24392029
Oncogene. 2004 Dec 9;23(57):9173-82
pubmed: 15516982
PLoS One. 2014 Apr 03;9(4):e93934
pubmed: 24699941
Cell Cycle. 2011 Dec 1;10(23):4047-64
pubmed: 22134189
Chem Biol Interact. 2007 May 1;167(3):193-206
pubmed: 17376416
Am J Transl Res. 2017 Aug 15;9(8):3816-3826
pubmed: 28861172
Nutr Cancer. 2006;54(1):111-42
pubmed: 16800779
Mol Cell Biol. 2013 Aug;33(16):3330-42
pubmed: 23775125
Cell Cycle. 2008 Sep 15;7(18):2936-41
pubmed: 18769157
Breast Cancer Res Treat. 2008 Jul;110(1):69-83
pubmed: 17674191
Nature. 2012 Feb 22;485(7396):55-61
pubmed: 22367541
Nutr Cancer. 1996;26(2):167-81
pubmed: 8875554
J Biol Chem. 2007 Mar 2;282(9):6001-11
pubmed: 17200110
J Biol Chem. 1998 Dec 25;273(52):35291-8
pubmed: 9857070
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18297-302
pubmed: 25489079
Cancer Res. 2007 Apr 1;67(7):2932-7
pubmed: 17409397
Oncol Rep. 2009 Nov;22(5):1109-17
pubmed: 19787228
Oncotarget. 2017 Aug 24;8(43):75025-75037
pubmed: 29088842
Mol Cancer Ther. 2015 Nov;14(11):2411-21
pubmed: 26333382
J Cell Biol. 2004 Jan 19;164(2):169-74
pubmed: 14718521
J Histochem Cytochem. 2011 Jun;59(6):615-29
pubmed: 21430259
J Biol Chem. 2013 Aug 16;288(33):24264-76
pubmed: 23814067
J Biol Chem. 2016 Dec 23;291(52):26875-26885
pubmed: 27875297
Diagn Mol Pathol. 1997 Feb;6(1):42-8
pubmed: 9028736
Cancer Cell Int. 2017 Sep 25;17:83
pubmed: 29021715
Haematologica. 2017 Apr;102(4):755-764
pubmed: 28104700
Neoplasia. 2014 May;16(5):390-402
pubmed: 25016594
Nucleic Acids Res. 2007;35(12):3879-92
pubmed: 17537817
Carcinogenesis. 2011 Apr;32(4):568-75
pubmed: 21304051
Biochem Biophys Res Commun. 2012 Oct 12;427(1):47-53
pubmed: 22975348
Oncogene. 2001 Jan 25;20(4):484-9
pubmed: 11313979
J Endocrinol. 2003 Apr;177(1):65-81
pubmed: 12697038
Oncotarget. 2017 May 9;8(19):32043-32054
pubmed: 28410191
Adv Exp Med Biol. 1998;439:227-36
pubmed: 9781306
Breast Cancer Res Treat. 2013 Jan;137(2):397-406
pubmed: 23242584
Curr Pharm Biotechnol. 2015;16(9):804-15
pubmed: 26201609
Tumour Biol. 2015 Aug;36(8):5743-52
pubmed: 26188905
Mol Nutr Food Res. 2012 May;56(5):761-74
pubmed: 22648623
Bull Cancer. 2014 Dec;101(12):1080-8
pubmed: 25475708
Biochem Biophys Res Commun. 2009 Dec 11;390(2):235-40
pubmed: 19788888
Am J Transl Res. 2017 Jun 15;9(6):3027-3036
pubmed: 28670390
Cell Cycle. 2010 Jan 15;9(2):364-70
pubmed: 20023423
J Biol Chem. 2016 Aug 26;291(35):18252-62
pubmed: 27387505
EMBO J. 2002 Jul 1;21(13):3443-53
pubmed: 12093745
J Clin Oncol. 2016 Nov 1;34(31):3803-3815
pubmed: 27621407
Anticancer Drugs. 2004 Aug;15(7):651-62
pubmed: 15269596
Molecules. 2017 Dec 20;22(12):
pubmed: 29261144
Oncol Rep. 2014 Jul;32(1):131-8
pubmed: 24859932
Mol Cell Biol. 2011 Mar;31(6):1160-73
pubmed: 21245388
Cell Cycle. 2004 Dec;3(12):1530-6
pubmed: 15539946
Cell Death Dis. 2014 Jan 02;5:e980
pubmed: 24384723
Mol Cancer Ther. 2008 May;7(5):1195-206
pubmed: 18483307
J Exp Med. 2013 Jul 1;210(7):1331-50
pubmed: 23752226
Oncotarget. 2016 Dec 27;7(52):86011-86025
pubmed: 27852068
Cancer Res. 2013 May 15;73(10):3062-74
pubmed: 23492364
Curr Cancer Drug Targets. 2009 Aug;9(5):639-51
pubmed: 19508171
Anticancer Res. 1995 Nov-Dec;15(6B):2899-905
pubmed: 8669886
Sci Rep. 2017 Nov 30;7(1):16684
pubmed: 29192143
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15046-51
pubmed: 18818310
Mol Carcinog. 2018 Dec;57(12):1751-1762
pubmed: 30136444
Bull Exp Biol Med. 2016 Apr;160(6):807-10
pubmed: 27165065
Crit Rev Oncol Hematol. 2015 Feb;93(2):116-26
pubmed: 25459672
Nutr Cancer. 2014;66(4):625-35
pubmed: 24734951
Clin Cancer Res. 2014 Jan 15;20(2):413-24
pubmed: 24173541
J Clin Oncol. 2005 Oct 10;23(29):7350-60
pubmed: 16145060
J Biol Chem. 2012 Mar 2;287(10):7010-25
pubmed: 22203677
J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):123-31
pubmed: 12943696
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Mol Cancer. 2015 Feb 15;14:43
pubmed: 25743390
BMC Cancer. 2014 Sep 11;14:664
pubmed: 25213022
J Clin Oncol. 2009 Jun 1;27(16):2712-25
pubmed: 19414669
J Cell Mol Med. 2016 Sep;20(9):1779-88
pubmed: 27097729
Int J Cancer. 2018 Feb 15;142(4):658-670
pubmed: 28975625
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5
pubmed: 17600087
Genes Dev. 2010 Jan 15;24(2):171-82
pubmed: 20080953
Mol Cancer Res. 2011 Aug;9(8):1091-9
pubmed: 21673012
Oncotarget. 2014 Jul 15;5(13):4603-50
pubmed: 25051360
Oncotarget. 2017 Jan 17;8(3):4422-4435
pubmed: 27779109
Oncogene. 2017 May 11;36(19):2680-2692
pubmed: 27893712
Mol Cell Endocrinol. 2016 Jul 15;430:56-67
pubmed: 27095481